FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,580,000 | -1.2% | 27,000 | 0.0% | 0.05% | +4.2% |
| Q3 2021 | $1,600,000 | -38.6% | 27,000 | -10.0% | 0.05% | -39.2% |
| Q2 2021 | $2,604,000 | +5.3% | 30,000 | 0.0% | 0.08% | +1.3% |
| Q1 2021 | $2,474,000 | -32.0% | 30,000 | -25.0% | 0.08% | -36.6% |
| Q4 2020 | $3,637,000 | +51.7% | 40,000 | -33.3% | 0.12% | +25.5% |
| Q3 2020 | $2,398,000 | +16.5% | 60,000 | 0.0% | 0.10% | +8.9% |
| Q2 2020 | $2,059,000 | +54.5% | 60,000 | 0.0% | 0.09% | +23.3% |
| Q1 2020 | $1,333,000 | -2.7% | 60,000 | -14.3% | 0.07% | +25.9% |
| Q4 2019 | $1,370,000 | +26.0% | 70,000 | 0.0% | 0.06% | +23.4% |
| Q3 2019 | $1,087,000 | -23.5% | 70,000 | 0.0% | 0.05% | -28.8% |
| Q2 2019 | $1,421,000 | +15.5% | 70,000 | 0.0% | 0.07% | +15.8% |
| Q1 2019 | $1,230,000 | +37.0% | 70,000 | 0.0% | 0.06% | +32.6% |
| Q4 2018 | $898,000 | -21.2% | 70,000 | 0.0% | 0.04% | -17.3% |
| Q3 2018 | $1,140,000 | +101.1% | 70,000 | +40.0% | 0.05% | +136.4% |
| Q2 2018 | $567,000 | – | 50,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |